Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New research supports efficacy of zincum gluconicum nasal gel


Significant reduction in severity and duration of cold symptoms

New research confirms the efficacy of zincum gluconicum nasal gel in reducing the severity and duration of common cold symptoms when treatment is started as late as the second day of illness. The study, which appears in the January issue of QJM: An International Journal of Medicine, was the first trial on the naturally acquired common cold to extend initiation of treatment beyond the first 24 hours of illness.

"All previous evaluations of zincum gluconicum nasal gel’s effect on the naturally acquired common cold limited initiation of treatment to the first 24 hours of symptoms," explained Sherif B. Mossad, MD, FACP, FIDSA, Department of Infectious Diseases, Cleveland Clinic Foundation. "We now have findings to document a significant reduction in severity and duration of symptoms even when treatment is started as late as 48 hours after onset of illness."

Dr. Mossad said his study adds to a growing body of evidence supporting the effectiveness of zincum gluconicum nasal gel in reducing nasal drainage, nasal congestion, sore throat, and other symptoms typical of virus-induced rhinitis (inflammation of the mucous membranes of the nose). However, he noted that his study is the first to include microbiological confirmation of rhinovirus infection with polymerase chain reaction--a highly sensitive test--as well as information related to the specific time of perceived improvement of individual symptoms.

"Among the subset of patients with confirmed rhinovirus infection, the zinc nasal gel-treated patients experienced a 50% reduction in time to cold resolution when compared to the placebo group," said Dr. Mossad.

"This is great news for busy cold sufferers who cannot always treat their illness during that initial 24-hour period," said Carl J. Johnson, president and chief executive officer of Matrixx Initiatives, Inc., the makers of Zicam® cold remedy zinc nasal gel products. "It’s encouraging to see the building body of scientific evidence that supports the efficacy of using zinc nasal gel to combat the common cold."

Study Design

The randomized, double-blind, placebo-controlled study was supported by an unrestricted grant from Matrixx Initiatives, Inc. The population included 78 patients, between the ages of 18 and 55, who had cold symptoms, but were otherwise in good health.

Patients were enrolled within 24 to 48 hours of onset of three or more of the following symptoms: nasal drainage, sore throat, nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, and fever (oral temperature greater than 98.6º F).

Forty patients were randomized to treatment with zincum gluconicum nasal gel, and 38 patients were randomized to the placebo group. Rhinitis was documented by physical exam. Eighteen of the 78 patients (23%)--seven in the zincum gluconicum group and 11 in the placebo group--had rhinovirus infection confirmed by microbiological testing of specimens obtained by nasal irrigation.

Patients administered one dose of nasal gel per nostril, four times per day. Treatment endpoints were either resolution of symptoms or completion of the maximum 10-day treatment period. Patients in the zincum gluconicum group used a total daily dose of about 2.1 mg of elemental zinc. Patients in the placebo group used a compound identical to the treatment formulation in all aspects except the active ingredient. Patients were not permitted to use other cold remedies during the study period, such as nonsteroidal anti-inflammatory drugs (e.g., aspirin and ibuprofen), decongestants, antihistamines, or other zinc products.

Study Findings

The median duration of cold symptoms was significantly shorter in the zincum gluconicum group (4.3 days) compared to the placebo group (6 days). Other research has documented a reduction in duration of symptoms as great as 75% when the treatment period was extended to as long as 14 days.*

"Patients randomized to the zincum gluconicum nasal gel group experienced a marked reduction in median time to cold resolution and duration of most individual symptoms compared with the placebo group," said Dr. Mossad. "Signs and symptoms that showed the most reduction were nasal drainage, nasal congestion, hoarseness, and sore throat."

Dr. Mossad noted that the overall incidence of adverse effects was low, with no statistically significant difference between the treated and placebo groups. Occasional nasal stinging or burning sensation was the most common adverse effect reported in both groups.

"We were particularly impressed by the absence of reported gastrointestinal symptoms, such as nausea, that have been described by people using oral formulations of zinc," said Dr. Mossad.

About the Common Cold

According to the National Institutes of Health, people suffer an estimated one billion colds in the United States each year. Adults average about two to four colds a year, although the range varies widely. More than 200 different viruses are known to cause the symptoms of the common cold. Cold viruses are typically transmitted by any or all of the following:

  • Touching infectious respiratory secretions on skin and on environmental surfaces and then touching the eyes or nose.
  • Inhaling relatively large particles of respiratory secretions transported briefly in the air.
  • Inhaling droplet nuclei: smaller infectious particles suspended in the air for long periods of time.

The nose is the main portal of entry for cold viruses. The highest concentration of cold virus in nasal secretions occurs during the first three days of infection. This is when infected persons are most contagious.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development, manufacture and marketing of innovative drug delivery systems for over-the-counter (OTC) pharmaceuticals. Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells Zicam® Cold Remedy nasal gel, a patented, homeopathic remedy that has been clinically proven to significantly reduce the duration and severity of the common cold. For more information regarding Matrixx products, go to To find out more about Matrixx Initiatives, Inc. (NASDAQ:MTXX), visit

*Hirt M, Nobel S, Ernesto B. Zinc nasal gel for the treatment of common cold symptoms: A double blind, placebo-controlled trial. ENT J 2000;79:778-82

To schedule an interview with Dr. Mossad, contact The Cleveland Clinic Department of Public and Media Relations at 216-444-0141.

Robert Murphy | EurekAlert!

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>